/SNBIF
SNBIF Stock - SanBio Company Limited
Healthcare|BiotechnologyOTC
$16.45+0.00%
+$0.00 (+0.00%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $18.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SNBIF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.29 – $16.61
TARGET (TP)$18.92
STOP LOSS$15.13
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.16
52W High$16.45
52W Low$3.85
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-14,504,000 | $-24,615,000 | $-132,467,000 | $-74,455,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,516,000,000 | $-4,539,729,000 | $-7,899,308,000 | $-6,620,884,000 | $-5,801,740,000 |
| Net Income | $-2,882,000,000 | $-2,644,332,000 | $-5,559,584,000 | $-4,677,856,000 | $-3,385,875,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-41.85 | $-40.48 | $-95.99 | $-90.33 | $-65.38 |
Company Overview
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SNBIFBeat Rate
100%
Last 4 quarters
Avg Surprise
+56.6%
EPS vs Estimate
Beats / Misses
4/0
Last 12 quarters
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
+88.2%
$-0.01vs$-0.12
Q3 24
+5.6%
$-0.12vs$-0.12
Q4 24
+33.2%
$-0.08vs$-0.12
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
+99.6%
$-0.00vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Dec 15, 2025 | $-0.10 | $-0.00 | +99.6% | ✓ BEAT |
Q3 2025 | Sep 12, 2025 | — | $-0.04 | — | — |
Q2 2025 | Jun 13, 2025 | — | $-0.15 | — | — |
Q1 2025 | Mar 17, 2025 | — | $-0.07 | — | — |
Q4 2024 | Dec 16, 2024 | $-0.12 | $-0.08 | +33.2% | ✓ BEAT |
Q3 2024 | Sep 17, 2024 | $-0.12 | $-0.12 | +5.6% | ✓ BEAT |
Q2 2024 | Jun 13, 2024 | $-0.12 | $-0.01 | +88.2% | ✓ BEAT |
Q1 2024 | Mar 18, 2024 | — | $-0.08 | — | — |
Q4 2023 | Oct 31, 2023 | — | $-0.01 | — | — |
Q3 2023 | Jul 31, 2023 | — | $-0.13 | — | — |
Q2 2023 | Apr 30, 2023 | — | $-0.07 | — | — |
Q1 2023 | Mar 16, 2023 | — | $-61.10 | — | — |
Q4 2022 | Dec 15, 2022 | — | $6.65 | — | — |
Q3 2022 | Sep 14, 2022 | — | $-32.28 | — | — |
Q2 2022 | Jun 14, 2022 | — | $-5.98 | — | — |
Q1 2022 | Mar 11, 2022 | — | $-30.17 | — | — |
Q4 2021 | Dec 15, 2021 | — | $-18.95 | — | — |
Q3 2021 | Sep 14, 2021 | — | $-24.60 | — | — |
Q2 2021 | Jun 14, 2021 | — | $-16.61 | — | — |
Latest News
Loading news...
Frequently Asked Questions about SNBIF
What is SNBIF's current stock price?
SanBio Company Limited (SNBIF) is currently trading at $16.45 per share. The stock has moved +0.00% today.
What is the analyst price target for SNBIF?
No analyst price targets are currently available for this stock.
What sector is SanBio Company Limited in?
SanBio Company Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is SNBIF's market cap?
SanBio Company Limited has a market capitalization of $1.18 billion, making it a small-cap company.
Does SNBIF pay dividends?
No, SanBio Company Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASCLF
Ascletis Pharma Inc.
$1.71
Mkt Cap: $1.6B
CRWRF
Craneware plc
$26.30
Mkt Cap: $0.9B
CSBTF
Kuros Biosciences AG
$38.34
Mkt Cap: $1.5B
CSPHF
CStone Pharmaceuticals
$0.89
Mkt Cap: $1.3B
IDRSF
Idorsia Ltd
$4.80
Mkt Cap: $1.1B
LJUIF
SSY Group Limited
$0.40
Mkt Cap: $1.2B
PBHDF
Paramount Bed Holdings Co., Ltd.
$19.74
Mkt Cap: $1.2B
PHGUF
Pharming Group N.V.
$1.65
Mkt Cap: $1.1B
PPTDF
PeptiDream Inc.
$12.80
Mkt Cap: $1.7B
TWAPF
Towa Pharmaceutical Co., Ltd.
$16.83
Mkt Cap: $0.8B
Explore stocks similar to SNBIF for comparison